Novanta Posts Strong Q2 2026 Growth, Acquires Riverpoint Medical
Event summary
- Novanta reported Q2 2026 revenue of $265.8M, up 10.3% YoY.
- Adjusted EBITDA rose 16.4% to $60.7M, with a margin of 22.8%.
- Acquired Riverpoint Medical, doubling recurring medical consumables business.
- Q3 guidance projects revenue growth over 21%, incorporating Riverpoint's contribution.
The big picture
Novanta's Q2 2026 results highlight robust organic growth and strategic acquisitions, reinforcing its position as a key supplier in medical and advanced industrial technology. The Riverpoint Medical acquisition significantly expands its recurring revenue base and end-market exposure, aligning with long-term secular trends in minimally invasive surgery.
What we're watching
- Integration Success
- How Novanta will integrate Riverpoint Medical to achieve immediate accretion.
- Market Expansion
- Whether the acquisition strengthens Novanta's position in minimally invasive surgery markets.
- Financial Performance
- The pace at which Novanta can sustain its strong revenue and margin growth.
Related topics